AU2013352179B2 - Computationally optimized broadly reactive antigens for H1N1 influenza - Google Patents

Computationally optimized broadly reactive antigens for H1N1 influenza Download PDF

Info

Publication number
AU2013352179B2
AU2013352179B2 AU2013352179A AU2013352179A AU2013352179B2 AU 2013352179 B2 AU2013352179 B2 AU 2013352179B2 AU 2013352179 A AU2013352179 A AU 2013352179A AU 2013352179 A AU2013352179 A AU 2013352179A AU 2013352179 B2 AU2013352179 B2 AU 2013352179B2
Authority
AU
Australia
Prior art keywords
seq
influenza
polypeptide
residues
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013352179A
Other languages
English (en)
Other versions
AU2013352179A1 (en
AU2013352179A8 (en
Inventor
Donald M. Carter Jr.
Corey J. CREVAR
Ted M. Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU2013352179A1 publication Critical patent/AU2013352179A1/en
Publication of AU2013352179A8 publication Critical patent/AU2013352179A8/en
Assigned to UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION reassignment UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Amend patent request/document other than specification (104) Assignors: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Application granted granted Critical
Publication of AU2013352179B2 publication Critical patent/AU2013352179B2/en
Priority to AU2018201876A priority Critical patent/AU2018201876A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2013352179A 2012-11-27 2013-11-27 Computationally optimized broadly reactive antigens for H1N1 influenza Ceased AU2013352179B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018201876A AU2018201876A1 (en) 2012-11-27 2018-03-15 Computationally optimized broadly reactive antigens for h1n1 influenza

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730186P 2012-11-27 2012-11-27
US61/730,186 2012-11-27
PCT/US2013/072279 WO2014085616A1 (en) 2012-11-27 2013-11-27 Computationally optimized broadly reactive antigens for h1n1 influenza

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018201876A Division AU2018201876A1 (en) 2012-11-27 2018-03-15 Computationally optimized broadly reactive antigens for h1n1 influenza

Publications (3)

Publication Number Publication Date
AU2013352179A1 AU2013352179A1 (en) 2015-05-14
AU2013352179A8 AU2013352179A8 (en) 2015-05-28
AU2013352179B2 true AU2013352179B2 (en) 2017-12-21

Family

ID=50773495

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013352179A Ceased AU2013352179B2 (en) 2012-11-27 2013-11-27 Computationally optimized broadly reactive antigens for H1N1 influenza
AU2018201876A Abandoned AU2018201876A1 (en) 2012-11-27 2018-03-15 Computationally optimized broadly reactive antigens for h1n1 influenza

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018201876A Abandoned AU2018201876A1 (en) 2012-11-27 2018-03-15 Computationally optimized broadly reactive antigens for h1n1 influenza

Country Status (13)

Country Link
US (3) US9309290B2 (enExample)
EP (1) EP2925773B1 (enExample)
JP (2) JP2016505538A (enExample)
KR (1) KR20150089005A (enExample)
CN (1) CN104797594A (enExample)
AU (2) AU2013352179B2 (enExample)
CA (1) CA2891682A1 (enExample)
HK (1) HK1212708A1 (enExample)
IN (1) IN2015DN03070A (enExample)
MX (1) MX2015005056A (enExample)
RU (1) RU2015124805A (enExample)
SG (1) SG11201503989PA (enExample)
WO (1) WO2014085616A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811103C (en) * 2010-09-14 2020-01-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
JP6113155B2 (ja) * 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
EP2831094B1 (en) 2012-03-30 2018-06-13 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
EP3233116A4 (en) * 2014-12-19 2018-05-30 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
WO2016201127A1 (en) 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
EP3464327A1 (en) 2016-06-03 2019-04-10 Sanofi Pasteur Inc. Modification of engineered influenza hemagglutinin polypeptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148511A1 (en) * 2009-06-24 2010-12-29 Medicago, Inc. Chimeric influenza virus-like particles comprising hemagglutinin
WO2012177760A1 (en) * 2011-06-20 2012-12-27 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
WO2013148164A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0111830B8 (pt) 2000-06-23 2021-05-25 American Cyanamid Co método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CA2598884A1 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
BRPI0613625A2 (pt) 2005-07-19 2011-01-18 Dow Global Technologies Inc vacinas da gripe recombinantes
US20090327170A1 (en) 2005-12-19 2009-12-31 Claudio Donati Methods of Clustering Gene and Protein Sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
EP2217064A4 (en) * 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
EA034733B1 (ru) * 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
US20120034253A1 (en) 2008-09-25 2012-02-09 Fraunhofer Usa, Inc. Influenza Vaccines, Antigens, Compositions, and Methods
WO2010036948A2 (en) 2008-09-26 2010-04-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Dna prime/inactivated vaccine boost immunization to influenza virus
KR101715418B1 (ko) 2009-04-03 2017-03-10 메리얼 인코포레이티드 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신
US20110184160A1 (en) * 2010-01-26 2011-07-28 Weiner David B Nucleic acid molecule encoding consensus influenza a hemagglutinin h1
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN102373184A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用
CA2811103C (en) * 2010-09-14 2020-01-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
US9234008B2 (en) 2012-02-07 2016-01-12 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
MY180109A (en) 2012-02-13 2020-11-23 Univ Pittsburgh Commonwealth Sys Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010148511A1 (en) * 2009-06-24 2010-12-29 Medicago, Inc. Chimeric influenza virus-like particles comprising hemagglutinin
WO2012177760A1 (en) * 2011-06-20 2012-12-27 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
WO2013148164A1 (en) * 2012-03-30 2013-10-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GenBank Accession No. ABD60856 *

Also Published As

Publication number Publication date
US20160166677A1 (en) 2016-06-16
CA2891682A1 (en) 2014-06-05
US9309290B2 (en) 2016-04-12
EP2925773B1 (en) 2018-12-26
AU2018201876A1 (en) 2018-04-12
AU2013352179A1 (en) 2015-05-14
SG11201503989PA (en) 2015-06-29
HK1212708A1 (zh) 2016-06-17
MX2015005056A (es) 2015-07-23
JP2016505538A (ja) 2016-02-25
US9566328B2 (en) 2017-02-14
RU2015124805A (ru) 2017-01-13
CN104797594A (zh) 2015-07-22
AU2013352179A8 (en) 2015-05-28
IN2015DN03070A (enExample) 2015-10-02
WO2014085616A1 (en) 2014-06-05
US10017544B2 (en) 2018-07-10
KR20150089005A (ko) 2015-08-04
US20170114102A1 (en) 2017-04-27
EP2925773A1 (en) 2015-10-07
EP2925773A4 (en) 2016-06-08
US20140147459A1 (en) 2014-05-29
JP2018183149A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
US10562940B2 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
US10865228B2 (en) Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
AU2013217166B2 (en) Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
US10017544B2 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
HK1203523B (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 29 , NO 18 , PAGE(S) 2709 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME, UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, APPLICATION NO.2013352179, UNDER INID (72) CORRECT THE COINVENTOR TO CREVAR, COREY J.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired